Morgan Stanley
DBTX

Morgan Stanley’s Decibel Therapeutics, Inc. Common Stock DBTX Stock Holding History

Morgan Stanley’s Portfolio DBTX Stock Details DBTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-6,600
Closed -$25.4K – 7750
2023
Q2 		$25.4K Sell
6,600
-9,526
-59% -$35K ﹤0.01% 6484
2023
Q1 		$48.7K Buy
16,126
+5,566
+53% +$19.2K ﹤0.01% 6297
2022
Q4 		$21.6K Sell
10,560
-1,512
-13% -$4.61K ﹤0.01% 6660
2022
Q3 		$42K Buy
12,072
+1,043
+9% +$4.75K ﹤0.01% 6485
2022
Q2 		$46K Sell
11,029
-11,812
-52% -$27.9K ﹤0.01% 6656
2022
Q1 		$69K Buy
22,841
+9,579
+72% +$36.7K ﹤0.01% 6538
2021
Q4 		$62K Sell
13,262
-14,892
-53% -$103K ﹤0.01% 6710
2021
Q3 		$217K Sell
28,154
-47,233
-63% -$361K ﹤0.01% 5961
2021
Q2 		$648K Buy
75,387
+67,984
+918% +$600K ﹤0.01% 5360
2021
Q1 		$84K Buy
+7,403
New +$116K ﹤0.01% 6104

Other funds holding DBTX

ACA
Atlas Capital Advisors Jackson, Wyoming $914M AUM

Morgan Stanley's DBTX Position: Q3 2023 in Review

Morgan Stanley sold out of Decibel Therapeutics, Inc. Common Stock (DBTX) in Q3 2023, closing a stake of 6,600 shares — an estimated $25.4K sold.

Morgan Stanley first reported a position in DBTX in Q1 2021 and held it in 10 quarters. The position peaked at $648K in Q2 2021. 1 fund tracked by Wall St. Rank holds DBTX as of Q3 2023.

  • Morgan Stanley reported no remaining Decibel Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • Morgan Stanley sold 6,600 Decibel Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $25.4K.
  • Morgan Stanley first reported a position in Decibel Therapeutics, Inc. Common Stock in Q1 2021 and held it in 10 quarters.
  • Morgan Stanley's Decibel Therapeutics, Inc. Common Stock position peaked at $648K in Q2 2021.
  • 1 fund tracked by Wall St. Rank held Decibel Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Morgan Stanley's 13F filing for Q3 2023, filed 15 Nov 2023.